Plus Therapeutics, Inc.(PSTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PSTV Plus Therapeutics, Inc.

Not Yet Opened 01-12 16:00:00 EST

0.4900

-0.0652

-11.74%

盘后0.4979

+0.0079+1.61%

19:59 EST

High0.5130	Low0.4749	Vol8.78M
Open0.5000	D1 Closing0.5552	Amplitude6.86%
Mkt Cap67.34M	Tradable Cap67.13M	Total Shares137.43M
T/O4.33M	T/O Rate6.41%	Tradable Shares137.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PSTV","market":"US","secType":"STK","nameCN":"Plus Therapeutics, Inc.","latestPrice":0.49,"timestamp":1768251600000,"preClose":0.5552,"halted":0,"volume":8783603,"hourTrading":{"tag":"盘后","latestPrice":0.4979,"preClose":0.49,"latestTime":"19:59 EST","volume":110706,"amount":54500.25704,"timestamp":1768265997179},"delay":0,"floatShares":137000000,"shares":137429055,"eps":-0.455966,"marketStatus":"Not Yet Opened","change":-0.0652,"latestTime":"01-12 16:00:00 EST","open":0.5,"high":0.513,"low":0.4749,"amount":4331302.15060072,"amplitude":0.068624,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.455966,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768294800000},"marketStatusCode":0,"adr":0,"listingDate":1134968400000,"exchange":"NASDAQ","adjPreClose":0.5552,"preHourTrading":{"tag":"盘前","latestPrice":0.5,"preClose":0.5552,"latestTime":"09:27 EST","volume":346895,"amount":172191.68806575,"timestamp":1768228041495},"postHourTrading":{"tag":"盘后","latestPrice":0.4979,"preClose":0.49,"latestTime":"19:59 EST","volume":110706,"amount":54500.25704,"timestamp":1768265997179},"volumeRatio":2.122489},"requestUrl":"/m/hq/s/PSTV","defaultTab":"news","newsList":[{"id":"2601361254","title":"BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2601361254","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601361254?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:57","pubTimestamp":1767877031,"startTime":"0","endTime":"0","summary":"BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA Jan 8 (Reuters) - Plus Therapeutics Inc PSTV.O:PLUS THERAPEUTICS ANNOUNCES READ OUT OF TYPE B MEETING WITH THE FDA WITH GOAL O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7R6D9B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2601369082","title":"Plus Therapeutics Announces Read Out of Type B Meeting With the FDA With Goal of Accelerating Approval of Reyobiq™ for Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369082?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:30","pubTimestamp":1767875400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7R6D9B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2601369034","title":"Plus Therapeutics Inc - FDA Recommends Study Evaluate Endpoint With Clinical Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369034","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369034?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:30","pubTimestamp":1767875400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7R6D9B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2601087369","title":"Plus Therapeutics Inc - FDA Indicates Accelerated Approval May Be Appropriate for Lm","url":"https://stock-news.laohu8.com/highlight/detail?id=2601087369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601087369?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:30","pubTimestamp":1767875400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7R6D9B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2590137965","title":"CNSide Diagnostics Expands CNSide Assay Platform to California","url":"https://stock-news.laohu8.com/highlight/detail?id=2590137965","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590137965?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456259,"startTime":"0","endTime":"0","summary":"Plus Therapeutics' Subsidiary CNSide Diagnostics Expands CNSide Assay Platform to California. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL37f8S3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014021.USD","BK4139","NDAQ","LU2095319765.USD","LU2210149790.SGD","PSTV","SG9999014039.USD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014013.SGD"],"gpt_icon":1},{"id":"2590710345","title":"Plus Therapeutics Grants Stock Options and RSUs to New CNSide Diagnostics Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2590710345","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590710345?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:30","pubTimestamp":1765283410,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Inc. has granted stock options and restricted stock units  to two new hires, Mr. Gurnani and Ms. Luckey, at its CNSide Diagnostics subsidiary. Each employee received options to purchase up to 33,750 shares of the company's common stock at the closing price on December 4, 2025. The options are set to vest over four years, with one-fourth vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL9CSPQn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD","BK4585","SG9999014021.USD","IE00B64PRP62.GBP","PSTV","LU2095319765.USD","SG9999014013.SGD","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","BK4112","LU2210150020.SGD","BK4139"],"gpt_icon":0},{"id":"2585462503","title":"Plus Therapeutics completes FDA meeting on REYOBIQ development plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462503?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:45","pubTimestamp":1763988355,"startTime":"0","endTime":"0","summary":"Plus Therapeutics (PSTV) completed a Type B meeting with the U.S. Food and Drug Administration on November 7th to discuss its REYOBIQ clinical deve...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-completes-fda-meeting-on-reyobiq-development-plans-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-completes-fda-meeting-on-reyobiq-development-plans-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","BK4007","PSTV"],"gpt_icon":0},{"id":"2585927141","title":"Plus Therapeutics Inc : Ascendiant Capital Markets Cuts Target Price to $19 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2585927141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585927141?lang=en_us&edition=fundamental","pubTime":"2025-11-21 15:23","pubTimestamp":1763709789,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WX0B2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2584139292","title":"Plus Therapeutics’ assay secures national coverage agreement with Humana","url":"https://stock-news.laohu8.com/highlight/detail?id=2584139292","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584139292?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:35","pubTimestamp":1763642142,"startTime":"0","endTime":"0","summary":"CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), has signed a national agreement with Humana (HUM), effective October 29,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-assay-secures-national-coverage-agreement-with-humana-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-assay-secures-national-coverage-agreement-with-humana-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HUM","BK4533","BK4566","LU0417517546.SGD","LU0320765489.SGD","LU0211331839.USD","BK4007","SG9999014005.SGD","BK4154","LU0348723411.USD","LU0238689110.USD","LU0208291251.USD","BK4585","BK4539","LU0390134368.USD","SG9999014013.SGD","LU1983260115.SGD","BK4588","BK4139","LENZ","LU0070302665.USD","LU0170899867.USD","LU1093756325.SGD","SG9999014021.USD","LU0256863811.USD","LU0266013472.USD","LU1093756168.USD","PSTV"],"gpt_icon":0},{"id":"2581786577","title":"Plus Therapeutics CFO Andrew Sims Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581786577","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581786577?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:30","pubTimestamp":1762349450,"startTime":"0","endTime":"0","summary":"Andrew John Hugh MacIntyre Sims, Chief Financial Officer of Plus Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL70Hyvt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2579177221","title":"Plus Therapeutics Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2579177221","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579177221?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:33","pubTimestamp":1761856428,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Q3 net loss widensOverviewPlus Therapeutics Q3 net loss widens to $4.4 mln from $2.9 mln last yearCompany received $1.9 mln advance from CPRIT for radiotherapeutic developmentAnnounc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL1N3WB1P4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0345770993.USD","LU1674673691.USD","LU0943347566.SGD","LU1814569148.SGD","IE00B19Z8X17.USD","LU2552382132.HKD","LU0128525929.USD","LU1674673428.USD","IE00B19Z3581.USD","LU0029864427.USD","IE00BWXC8680.SGD","LU1732800096.USD","LU2552382058.USD","LU0820561818.USD","PSTV","LU0683600562.USD","IE00B2B36J28.USD","LU0320765059.SGD","IE00BFSS7M15.SGD","LU0708995401.HKD","LU2552382215.SGD","LU2133065610.SGD","IE00B19Z9505.USD","IE00BJJMRX11.SGD","LU0211326839.USD","LU0354030511.USD","LU1551013342.USD","LU0187121727.USD","LU0354030438.USD","LU1267930573.SGD","SG9999001176.USD","LU0965509010.AUD","LU1718418525.SGD","IE000M9KFDE8.USD","LU1914381329.SGD","LU0234572021.USD","LU0861579265.USD","LU0345770308.USD","LU0882574055.USD","LU1057294990.SGD","LU0795875086.SGD","LU2112291526.USD","LU0094547139.USD","IE00BKVL7J92.USD","LU0211326755.USD","LU0432979614.USD","LU0820562030.AUD","LU2125154778.USD"],"gpt_icon":1},{"id":"2579717725","title":"Plus Therapeutics Q3 Net Income USD -4.423 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2579717725","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579717725?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:32","pubTimestamp":1761856332,"startTime":"0","endTime":"0","summary":"Oct 30 (Reuters) - Plus Therapeutics Q3 operating expenses USD 5.879 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 30-OCT-202520:15:48.467 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nRSD5bGQrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2579622172","title":"Plus Therapeutics Q3 Operating Income USD -4.482 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2579622172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579622172?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:15","pubTimestamp":1761855303,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nPLX3BE2EA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2579172325","title":"Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2579172325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579172325?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:15","pubTimestamp":1761855303,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUA6VWPH7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2577227288","title":"Plus Therapeutics provides update on CNSide Diagnostic platform launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2577227288","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577227288?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:40","pubTimestamp":1761046836,"startTime":"0","endTime":"0","summary":"Plus Therapeutics (PSTV) announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Dia...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-provides-update-on-cnside-diagnostic-platform-launch-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-provides-update-on-cnside-diagnostic-platform-launch-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSTV","LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2577282400","title":"Press Release: Plus Therapeutics Updates on CNSide(R) Diagnostic Platform Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2577282400","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577282400?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:30","pubTimestamp":1761046200,"startTime":"0","endTime":"0","summary":"Appoints new leadership in commercial strategy and technical operations. HOUSTON, Oct. 21, 2025  -- Plus Therapeutics, Inc.  , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system  cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid  Tumor Cell Enumeration laboratory developed test .Recent accomplishments include expansion of the CNSide manufacturing footprint, advancements in commercial readiness and appointments in key leadership positions to propel the CNSide diagnostic business forward. To lead commercialization strategy, Russ Havranek, MS, MBA, has been promoted to Executive Vice President, Commercial and Corporate Strategy. In addition, Daniel Ortega, MBA, has been promoted to the position of Vice President, Development and Technical Operations to lead our diagnostic capabilities a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4023","BK4232","BK4139","BK4585","BK4135","PSTV","STRK","BK4007","BK4600","CNS","LENZ","BK4595","BK4588","BK4596","BK4516","BK4022","R","CSF"],"gpt_icon":1},{"id":"2570009463","title":"Plus Therapeutics announces national coverage agreement with UnitedHealthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2570009463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570009463?lang=en_us&edition=fundamental","pubTime":"2025-09-25 19:40","pubTimestamp":1758800456,"startTime":"0","endTime":"0","summary":"CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), announced that it has signed a national agreement with UnitedHealthcare ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-announces-national-coverage-agreement-with-unitedhealthcare-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-announces-national-coverage-agreement-with-unitedhealthcare-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","PSTV","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2570094853","title":"Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit","url":"https://stock-news.laohu8.com/highlight/detail?id=2570094853","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570094853?lang=en_us&edition=fundamental","pubTime":"2025-09-25 19:31","pubTimestamp":1758799860,"startTime":"0","endTime":"0","summary":"CNSide Diagnostics, a wholly-owned subsidiary ofPlus Therapeutics, Inc. , has signed a national agreement with UnitedHealthcare insurance company, a unit of UnitedHealth Group Inc. .EffectiveSeptember 15, the agreement covers over 51 million people throughoutthe United States, providing the CNSide Cerebrospinal Fluid  Tumor Cell Enumeration laboratory developed test .The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.The superior clinical utility of CNSide over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.Also Read: Why Plus Therapeutics  Shares Are Exploding Higher. More than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.Last week, CNS","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/25/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/25/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/09/47861805/plus-therapeutics-national-coverage-agreement-with-unitedhealthcare-cns-cancer-diagnostic-kit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/09/47861805/plus-therapeutics-national-coverage-agreement-with-unitedhealthcare-cns-cancer-diagnostic-kit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["IE00BFSS8Q28.SGD","LU1778281490.HKD","LU2211815571.USD","LU0320765059.SGD","LU0787776722.HKD","LU0353189680.USD","IE00BZ9MQY76.HKD","LU0149725797.USD","SG9999013999.USD","LU0342679015.USD","LU1854104046.USD","LU2362541273.HKD","LU0211327993.USD","LU1066051498.USD","LU1064131342.USD","LU2491050071.SGD","LU2112291526.USD","IE00B894F039.SGD","LU0158827948.USD","LU0011850046.USD","CNS","LU0128525689.USD","LU0310799852.SGD","IE00BZ1G4Q59.USD","LU0256863811.USD","IE00B7KXQ091.USD","LU2461242641.AUD","SGXZ99366536.SGD","IE00B2B36J28.USD","LU1506573853.SGD","LU0198837287.USD","LU2125154778.USD","LU0965509101.SGD","NHLD","LU2552382215.SGD","SG9999014906.USD","IE000M9KFDE8.USD","PSTV","SGXZ51526630.SGD","LU1551013425.SGD","LU1814569148.SGD","LU0094547139.USD","SG9999014898.SGD","LU0310800379.SGD","LENZ","LU0683600562.USD","LU1988902786.USD","CSF","IE00B4JS1V06.HKD"],"gpt_icon":1},{"id":"2570091129","title":"Plus Therapeutics Announces National Coverage Agreement With Unitedhealthcare Insurance Company for Cnside® Cerebrospinal Fluid Assay for Metastatic CNS Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2570091129","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570091129?lang=en_us&edition=fundamental","pubTime":"2025-09-25 19:30","pubTimestamp":1758799800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nTUA1K8YHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066053197.SGD","LU1066051811.HKD","UNH","LU1548497426.USD","IE00BN29S564.USD","LU1057294990.SGD","LU0158827781.USD","LU1778281490.HKD","IE00B4JS1V06.HKD","LU2087625088.SGD","LU2133065610.SGD","LU2468319806.SGD","PSTV","LU1854104046.USD","LU1066051225.USD","IE0002270589.USD","LU2552382132.HKD","IE00BFSS8Q28.SGD","LU2242649171.HKD","LU0310800965.SGD","IE00BFTCPJ56.SGD","LU0149725797.USD","LU0251132253.USD","LU0965509283.SGD","LU1814569148.SGD","LU1934455863.HKD","SG9999013999.USD","LU0353189680.USD","LU1069347547.HKD","IE00BWXC8680.SGD","BK4581","SG9999018865.SGD","LU1061106388.HKD","LU0053666078.USD","LU1670627923.USD","LU2211815571.USD","LU1003077747.HKD","SG9999014914.USD","IE00B894F039.SGD","LU0820562030.AUD","LU1732800096.USD","SG9999014906.USD","SG9999017495.SGD","IE00B7KXQ091.USD","IE00B775H168.HKD","IE00B19Z3B42.SGD","IE00BFSS7M15.SGD","LU0965509010.AUD","IE0005OL40V9.USD","LU2552382058.USD"],"gpt_icon":0},{"id":"2569978977","title":"Plus Therapeutics Announces Additional $1.9 Million Advance Payment From Cprit","url":"https://stock-news.laohu8.com/highlight/detail?id=2569978977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569978977?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:31","pubTimestamp":1758540675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nFWN3V70GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://plustherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1264},{"period":"1month","weight":-0.2834},{"period":"3month","weight":-0.3031},{"period":"6month","weight":0.5123},{"period":"1year","weight":-0.5776},{"period":"ytd","weight":-0.0435}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.086322},{"month":2,"riseRate":0.521739,"avgChangeRate":0.019388},{"month":3,"riseRate":0.391304,"avgChangeRate":-0.044696},{"month":4,"riseRate":0.347826,"avgChangeRate":-0.02768},{"month":5,"riseRate":0.478261,"avgChangeRate":0.361181},{"month":6,"riseRate":0.25,"avgChangeRate":-0.076657},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.003883},{"month":8,"riseRate":0.291667,"avgChangeRate":-0.04175},{"month":9,"riseRate":0.541667,"avgChangeRate":-0.030103},{"month":10,"riseRate":0.291667,"avgChangeRate":-0.062759},{"month":11,"riseRate":0.375,"avgChangeRate":0.007725},{"month":12,"riseRate":0.375,"avgChangeRate":-0.028095}],"exchange":"NASDAQ","name":"Plus Therapeutics, Inc.","nameEN":"Plus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Plus Therapeutics, Inc.(PSTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Plus Therapeutics, Inc.(PSTV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Plus Therapeutics, Inc.,PSTV,Plus Therapeutics, Inc.股票,Plus Therapeutics, Inc.股票老虎,Plus Therapeutics, Inc.股票老虎国际,Plus Therapeutics, Inc.行情,Plus Therapeutics, Inc.股票行情,Plus Therapeutics, Inc.股价,Plus Therapeutics, Inc.股市,Plus Therapeutics, Inc.股票价格,Plus Therapeutics, Inc.股票交易,Plus Therapeutics, Inc.股票购买,Plus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Plus Therapeutics, Inc.(PSTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Plus Therapeutics, Inc.(PSTV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction